Postoperative nonspecific immunotherapy in primary bronchogenic carcinoma

Area of Science:

• Oncology
• Immunology
• Microbiology

Background:

• Primary bronchogenic carcinoma (lung cancer) poses significant challenges in postoperative patient outcomes.
• Adjuvant therapies are crucial for improving survival rates after surgical resection of lung cancer.

Purpose of the Study:

• To evaluate the efficacy of postoperative active nonspecific immunotherapy in patients with primary bronchogenic carcinoma.
• To assess the impact of M. smegmatis ATCC 607 immunotherapy on patient survival and comfort.

Main Methods:

• A cohort of 54 patients undergoing surgery for primary bronchogenic carcinoma received active nonspecific immunotherapy postoperatively.
• The immunopotentiator utilized was derived from a transformed strain of M. smegmatis ATCC 607.
• Survival rates were compared against a control group and historical data from over 20,000 patients.

Main Results:

• Patients receiving M. smegmatis ATCC 607 immunotherapy demonstrated a 60% increase in 1-year survival and a 50% increase in 2-year survival.
• These survival improvements were statistically significant when compared to control groups and extensive historical surgical series.
• An appreciable improvement in patient comfort was also observed in the treated group.

Conclusions:

• Postoperative active nonspecific immunotherapy with M. smegmatis ATCC 607 is a promising adjuvant treatment for primary bronchogenic carcinoma.
• This immunotherapy significantly enhances patient survival rates and improves overall well-being after lung cancer surgery.
• Further research into mycobacterial immunotherapy for lung cancer is warranted.